Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib in subjects with elevated Lp(a)
NCT02241772Phase 2Completed
- Sponsor
- Xention Ltd.
- Start
- Sep 2014
- Primary completion
- Jan 2015
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of obicetrapib in Hyperlipoproteinemia a, sponsored by Xention Ltd.. Started Sep 2014; status: completed.
02
Drugs
obicetrapib
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT02241772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02241772.